{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:47:59Z","timestamp":1782874079387,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF\u2013 2022R1C1C2005248"],"award-info":[{"award-number":["NRF\u2013 2022R1C1C2005248"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2019-NR40073"],"award-info":[{"award-number":["RS-2019-NR40073"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04450-x","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:15:26Z","timestamp":1778170526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor-targeted liposomal RNAi therapy suppresses breast cancer and modulates tumor microenvironment"],"prefix":"10.1186","volume":"24","author":[{"given":"Sujeong","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Bang","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae Won","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungsun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyuwon","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Soon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Hong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"1","key":"4450_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41946-8","volume":"14","author":"Y Li","year":"2023","unstructured":"Li Y, Ji T, Torre M, Shao R, Zheng Y, Wang D, et al. Aromatized liposomes for sustained drug delivery. Nat Commun. 2023;14(1):6659. https:\/\/doi.org\/10.1038\/s41467-023-41946-8.","journal-title":"Nat Commun"},{"key":"4450_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12030264","author":"MK Lee","year":"2020","unstructured":"Lee MK. Liposomes for enhanced bioavailability of water-insoluble drugs: in vivo evidence and recent approaches. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12030264.","journal-title":"Pharmaceutics"},{"key":"4450_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17070885","author":"Z Sobol","year":"2025","unstructured":"Sobol Z, Chiczewski R, Watrobska-Swietlikowska D. Advances in liposomal drug delivery: multidirectional perspectives on overcoming biological barriers. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/pharmaceutics17070885.","journal-title":"Pharmaceutics"},{"key":"4450_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cocis.2024.101875","author":"R Eugster","year":"2025","unstructured":"Eugster R, Luciani P. Liposomes: bridging the gap from lab to pharmaceuticals. Curr Opin Colloid Interface Sci. 2025. https:\/\/doi.org\/10.1016\/j.cocis.2024.101875.","journal-title":"Curr Opin Colloid Interface Sci"},{"issue":"1","key":"4450_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02368-w","volume":"24","author":"KM Abdullah","year":"2025","unstructured":"Abdullah KM, Sharma G, Singh AP, Siddiqui JA. Nanomedicine in cancer therapeutics: current perspectives from bench to bedside. Mol Cancer. 2025;24(1):169. https:\/\/doi.org\/10.1186\/s12943-025-02368-w.","journal-title":"Mol Cancer"},{"issue":"14","key":"4450_CR6","doi-asserted-by":"publisher","first-page":"8270","DOI":"10.1039\/d4nr05114a","volume":"17","author":"L Peng","year":"2025","unstructured":"Peng L, Gao Z, Liang Y, Guo X, Zhang Q, Cui D. Nanoparticle-based drug delivery systems: opportunities and challenges in the treatment of esophageal squamous cell carcinoma (ESCC). Nanoscale. 2025;17(14):8270\u201388. https:\/\/doi.org\/10.1039\/d4nr05114a.","journal-title":"Nanoscale"},{"key":"4450_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101583","volume":"31","author":"H Cheng","year":"2025","unstructured":"Cheng H, Liao J, Ma Y, Sarwar MT, Yang H. Advances in targeted therapy for tumor with nanocarriers: a review. Mater Today Bio. 2025;31:101583. https:\/\/doi.org\/10.1016\/j.mtbio.2025.101583.","journal-title":"Mater Today Bio"},{"issue":"1","key":"4450_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01536-y","volume":"8","author":"D Fan","year":"2023","unstructured":"Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Nanomedicine in cancer therapy. Signal Transduct Target Ther. 2023;8(1):293. https:\/\/doi.org\/10.1038\/s41392-023-01536-y.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4450_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03695-0","volume":"25","author":"J Jiang","year":"2025","unstructured":"Jiang J, Chen Y, Zheng Y, Ding Y, Wang H, Zhou Q, et al. Sialic acid metabolism-based classification reveals novel metabolic subtypes with distinct characteristics of tumor microenvironment and clinical outcomes in gastric cancer. Cancer Cell Int. 2025;25(1):61. https:\/\/doi.org\/10.1186\/s12935-025-03695-0.","journal-title":"Cancer Cell Int"},{"key":"4450_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1487306","volume":"14","author":"IF Habeeb","year":"2024","unstructured":"Habeeb IF, Alao TE, Delgado D, Buffone A. When a negative (charge) is not a positive: sialylation and its role in cancer mechanics and progression. Front Oncol. 2024;14:1487306. https:\/\/doi.org\/10.3389\/fonc.2024.1487306.","journal-title":"Front Oncol"},{"key":"4450_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00174","volume":"8","author":"ST Teoh","year":"2018","unstructured":"Teoh ST, Ogrodzinski MP, Ross C, Hunter KW, Lunt SY. Sialic acid metabolism: a key player in breast cancer metastasis revealed by metabolomics. Front Oncol. 2018;8:174. https:\/\/doi.org\/10.3389\/fonc.2018.00174.","journal-title":"Front Oncol"},{"issue":"9","key":"4450_CR12","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.7150\/thno.104558","volume":"15","author":"M Radan","year":"2025","unstructured":"Radan M, Carev I, Milos M, Tranfic Bakic M. Phenylboronic acid in targeted cancer therapy and diagnosis. Theranostics. 2025;15(9):3733\u201348. https:\/\/doi.org\/10.7150\/thno.104558.","journal-title":"Theranostics"},{"issue":"1","key":"4450_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56507-4","volume":"16","author":"L Dai","year":"2025","unstructured":"Dai L, Liu J, Yang T, Yu X, Lu Y, Pan L, et al. Lipoic acid-boronophenylalanine-derived multifunctional vesicles for cancer chemoradiotherapy. Nat Commun. 2025;16(1):1329. https:\/\/doi.org\/10.1038\/s41467-025-56507-4.","journal-title":"Nat Commun"},{"issue":"8","key":"4450_CR14","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1021\/acsabm.0c00530","volume":"3","author":"T Khan","year":"2020","unstructured":"Khan T, Igarashi K, Tanabe A, Miyazawa T, Fukushima S, Miura Y, et al. Structural control of boronic acid ligands enhances intratumoral targeting of sialic acid to eradicate cancer stem-like cells. ACS Appl Bio Mater. 2020;3(8):5030\u20139. https:\/\/doi.org\/10.1021\/acsabm.0c00530.","journal-title":"ACS Appl Bio Mater"},{"issue":"3","key":"4450_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1039\/d4pm00005f","volume":"1","author":"V Muripiti","year":"2024","unstructured":"Muripiti V, Ravula V, Batthula S, Banothu J, Gondru R. Phenylboronic acid-derived nanovectors for gene\/drug delivery by targeting cell surface glycans. RSC Pharm. 2024;1(3):403\u201311. https:\/\/doi.org\/10.1039\/d4pm00005f.","journal-title":"RSC Pharm"},{"key":"4450_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2021.101083","author":"X Tang","year":"2021","unstructured":"Tang X, Sheng Q, Xu C, Li M, Rao J, Wang X, et al. pH\/ATP cascade-responsive nano-courier with efficient tumor targeting and siRNA unloading for photothermal-immunotherapy. Nano Today. 2021. https:\/\/doi.org\/10.1016\/j.nantod.2021.101083.","journal-title":"Nano Today"},{"issue":"49","key":"4450_CR17","doi-asserted-by":"publisher","first-page":"20927","DOI":"10.1021\/jacs.1c09741","volume":"143","author":"R Wang","year":"2021","unstructured":"Wang R, Yin C, Liu C, Sun Y, Xiao P, Li J, et al. Phenylboronic acid modification augments the lysosome escape and antitumor efficacy of a cylindrical polymer brush-based prodrug. J Am Chem Soc. 2021;143(49):20927\u201338. https:\/\/doi.org\/10.1021\/jacs.1c09741.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"4450_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20075-0","volume":"12","author":"HJ Hwang","year":"2022","unstructured":"Hwang HJ, Hong SH, Moon HS, Yoon YE, Park SY. Ginsenoside Rh2 sensitizes the anti-cancer effects of sunitinib by inducing cell cycle arrest in renal cell carcinoma. Sci Rep. 2022;12(1):19752. https:\/\/doi.org\/10.1038\/s41598-022-20075-0.","journal-title":"Sci Rep"},{"key":"4450_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27175602","author":"H Li","year":"2022","unstructured":"Li H, Han C, Chen C, Han G, Li Y. (20S) ginsenoside Rh2-activated, distinct apoptosis pathways in highly and poorly differentiated human esophageal cancer cells. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27175602.","journal-title":"Molecules"},{"issue":"1","key":"4450_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-021-01062-5","volume":"19","author":"H Wang","year":"2021","unstructured":"Wang H, Zheng Y, Sun Q, Zhang Z, Zhao M, Peng C, et al. Ginsenosides emerging as both bifunctional drugs and nanocarriers for enhanced antitumor therapies. J Nanobiotechnol. 2021;19(1):322. https:\/\/doi.org\/10.1186\/s12951-021-01062-5.","journal-title":"J Nanobiotechnol"},{"key":"4450_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125334","volume":"672","author":"S Hu","year":"2025","unstructured":"Hu S, Sun D, Tang L, Kong L, Liu Y, Liu F, et al. Follicle-stimulating hormone peptide-conjugated liposomes in the treatment of epithelial ovarian cancer through the induction of M2-to-M1 macrophage repolarization. Int J Pharm. 2025;672:125334. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125334.","journal-title":"Int J Pharm"},{"issue":"1","key":"4450_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s40820-020-00472-8","volume":"12","author":"C Hong","year":"2020","unstructured":"Hong C, Liang J, Xia J, Zhu Y, Guo Y, Wang A, et al. One stone four birds: a novel liposomal delivery system multi-functionalized with ginsenoside Rh2 for tumor targeting therapy. Nanomicro Lett. 2020;12(1):129. https:\/\/doi.org\/10.1007\/s40820-020-00472-8.","journal-title":"Nanomicro Lett"},{"issue":"1","key":"4450_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-024-00813-y","volume":"30","author":"X Liu","year":"2024","unstructured":"Liu X, Li J, Huang Q, Jin M, Huang G. <article-title update=\"added\">Ginsenoside Rh2 shifts tumor metabolism from aerobic glycolysis to oxidative phosphorylation through regulating the HIF1-\u03b1\/PDK4 axis in non-small cell lung cancer. Mol Med. 2024;30(1):56. https:\/\/doi.org\/10.1186\/s10020-024-00813-y.","journal-title":"Mol Med"},{"key":"4450_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jff.2017.03.013","volume":"32","author":"F Chen","year":"2017","unstructured":"Chen F, Sun Y, Zheng S-L, Qin Y, Julian McClements D, Hu J-N, Deng Z-Y. Antitumor and immunomodulatory effects of ginsenoside Rh2 and its octyl ester derivative in H22 tumor-bearing mice. J Funct Foods. 2017;32:382\u201390. https:\/\/doi.org\/10.1016\/j.jff.2017.03.013.","journal-title":"J Funct Foods"},{"issue":"2","key":"4450_CR25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3892\/ol.2016.5490","volume":"13","author":"M Wang","year":"2017","unstructured":"Wang M, Yan SJ, Zhang HT, Li N, Liu T, Zhang YL, Li XX, Ma Q, Qiu XC, Fan QY, Ma BA. Ginsenoside Rh2 enhances the antitumor immunological response of a melanoma mice model. Oncol Lett. 2017;13(2):681\u20135. https:\/\/doi.org\/10.3892\/ol.2016.5490.","journal-title":"Oncol Lett"},{"key":"4450_CR26","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.2147\/IJN.S437733","volume":"19","author":"C Hong","year":"2024","unstructured":"Hong C, Wang A, Xia J, Liang J, Zhu Y, Wang D, et al. Ginsenoside Rh2-based multifunctional liposomes for advanced breast cancer therapy. Int J Nanomed. 2024;19:2879\u201388. https:\/\/doi.org\/10.2147\/IJN.S437733.","journal-title":"Int J Nanomed"},{"issue":"1","key":"4450_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43674-w","volume":"9","author":"SL Verstraeten","year":"2019","unstructured":"Verstraeten SL, Deleu M, Janikowska-Sagan M, Claereboudt EJS, Lins L, Tyteca D, et al. The activity of the saponin ginsenoside Rh2 is enhanced by the interaction with membrane sphingomyelin but depressed by cholesterol. Sci Rep. 2019;9(1):7285. https:\/\/doi.org\/10.1038\/s41598-019-43674-w.","journal-title":"Sci Rep"},{"key":"4450_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105917","author":"M Liu","year":"2024","unstructured":"Liu M, Li S-t, Wang J-h, Chen M-h, Zhang Z-x, Liu Y, et al. Methotrexate-modified docetaxel liposome targeting with ginsenoside Rh2 as a membrane stabilizer for the treatment of ovarian cancer. J Drug Deliv Sci Technol. 2024. https:\/\/doi.org\/10.1016\/j.jddst.2024.105917.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"4450_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02112-8","volume":"10","author":"M Liu","year":"2025","unstructured":"Liu M, Wang Y, Zhang Y, Hu D, Tang L, Zhou B, et al. Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines. Signal Transduct Target Ther. 2025;10(1):73. https:\/\/doi.org\/10.1038\/s41392-024-02112-8.","journal-title":"Signal Transduct Target Ther"},{"key":"4450_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106981","volume":"205","author":"GW Choi","year":"2025","unstructured":"Choi GW, Kim JH, Kang DW, Cho HY. A journey into siRNA therapeutics development: a focus on pharmacokinetics and pharmacodynamics. Eur J Pharm Sci. 2025;205:106981. https:\/\/doi.org\/10.1016\/j.ejps.2024.106981.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"4450_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.145461","volume":"319","author":"KK Abla","year":"2025","unstructured":"Abla KK, Zahwi M, El-Lakany SA, Karam M. Advances in siRNA-loaded liposomes for lung cancer: challenges and future perspectives. Int J Biol Macromol. 2025;319(1):145461. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.145461.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"4450_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21442-7","volume":"12","author":"F Li","year":"2021","unstructured":"Li F, Yu W, Zhang J, Dong Y, Ding X, Ruan X, et al. Spatiotemporally programmable cascade hybridization of hairpin DNA in polymeric nanoframework for precise siRNA delivery. Nat Commun. 2021;12(1):1138. https:\/\/doi.org\/10.1038\/s41467-021-21442-7.","journal-title":"Nat Commun"},{"issue":"6","key":"4450_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw8922","volume":"5","author":"C Liu","year":"2019","unstructured":"Liu C, Wan T, Wang H, Zhang S, Ping Y, Cheng Y. A boronic acid\u2013rich dendrimer with robust and unprecedented efficiency for cytosolic protein delivery and CRISPR-Cas9 gene editing. Sci Adv. 2019;5(6):eaaw8922. https:\/\/doi.org\/10.1126\/sciadv.aaw8922.","journal-title":"Sci Adv"},{"issue":"1","key":"4450_CR34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3892\/ijmm.2015.2395","volume":"37","author":"X Wang","year":"2016","unstructured":"Wang X, Li X, Zeng YN, He F, Yang XM, Guan F. Enhanced expression of polysialic acid correlates with malignant phenotype in breast cancer cell lines and clinical tissue samples. Int J Mol Med. 2016;37(1):197\u2013206. https:\/\/doi.org\/10.3892\/ijmm.2015.2395.","journal-title":"Int J Mol Med"},{"issue":"22","key":"4450_CR35","doi-asserted-by":"publisher","first-page":"9720","DOI":"10.1021\/acs.nanolett.1c03608","volume":"21","author":"D Mohammed","year":"2021","unstructured":"Mohammed D, Koehler M, Dumitru AC, Aravamudhan P, Sutherland DM, Dermody TS, et al. Altered glycan expression on breast cancer cells facilitates infection by T3 seroptype oncolytic reovirus. Nano Lett. 2021;21(22):9720\u20138. https:\/\/doi.org\/10.1021\/acs.nanolett.1c03608.","journal-title":"Nano Lett"},{"key":"4450_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.00013","volume":"8","author":"CT Saeui","year":"2020","unstructured":"Saeui CT, Cho KC, Dharmarha V, Nairn AV, Galizzi M, Shah SR, et al. Cell line-, protein-, and sialoglycosite-specific control of flux-based sialylation in human breast cells: implications for cancer progression. Front Chem. 2020;8:13. https:\/\/doi.org\/10.3389\/fchem.2020.00013.","journal-title":"Front Chem"},{"issue":"5","key":"4450_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195812","volume":"13","author":"CT Saeui","year":"2018","unstructured":"Saeui CT, Nairn AV, Galizzi M, Douville C, Gowda P, Park M, et al. Integration of genetic and metabolic features related to sialic acid metabolism distinguishes human breast cell subtypes. PLoS One. 2018;13(5):e0195812. https:\/\/doi.org\/10.1371\/journal.pone.0195812.","journal-title":"PLoS One"},{"issue":"12","key":"4450_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.427","volume":"7","author":"X Ma","year":"2016","unstructured":"Ma X, Dong W, Su Z, Zhao L, Miao Y, Li N, et al. Functional roles of sialylation in breast cancer progression through miR-26a\/26b targeting ST8SIA4. Cell Death Dis. 2016;7(12):e2561. https:\/\/doi.org\/10.1038\/cddis.2016.427.","journal-title":"Cell Death Dis"},{"key":"4450_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1483896","volume":"15","author":"R Ding","year":"2024","unstructured":"Ding R, Kan Q, Wang T, Xiao R, Song Y, Li D. Ginsenoside Rh2 regulates triple-negative breast cancer proliferation and apoptosis via the IL-6\/JAK2\/STAT3 pathway. Front Pharmacol. 2024;15:1483896. https:\/\/doi.org\/10.3389\/fphar.2024.1483896.","journal-title":"Front Pharmacol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04450-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04450-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04450-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:26:27Z","timestamp":1782872787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04450-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4450"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04450-x","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"597"}}